Judith A. Finegold

Neelan Das1
Jonathan Freedman1
1Neelan Das
1Jonathan Freedman
Learn More
BACKGROUND Ischaemic heart disease (IHD) is the leading cause of death worldwide. The World Health Organisation (WHO) collects mortality data coded using the International Statistical Classification of Diseases (ICD) code. METHODS We analysed IHD deaths world-wide between 1995 and 2009 and used the UN population database to calculate age-specific and(More)
OBJECTIVE When advising patients about possible initiation of primary prevention treatment, clinicians currently do not have information on expected impact on lifespan, nor how much this increment differs between individuals. METHODS First, UK cardiovascular and non-cardiovascular mortality data were used to calculate the mean lifespan gain from an(More)
BACKGROUND Renal denervation (RDN) may lower blood pressure (BP); however, it is unclear whether medication changes may be confounding results. Furthermore, limited data exist on pattern of ambulatory blood pressure (ABP) response-particularly in those prescribed aldosterone antagonists at the time of RDN. METHODS We examined all patients treated with RDN(More)
In clinical practice, echocardiographers are often unkeen to make the significant time investment to make additional multiple measurements of Doppler velocity. Main hurdle to obtaining multiple measurements is the time required to manually trace a series of Doppler traces. To make it easier to analyze more beats, we present the description of an application(More)
OBJECTIVES The goal of this study was to examine the impact of calculation-window duration on lifespan gain (as observed in trials) and on who gains most. BACKGROUND The landmark trials of biventricular pacing (cardiac resynchronization therapy [CRT]) typically ran for <1 device battery life, and they may therefore underestimate lifespan benefit over(More)
  • 1